Table 2. Results of overall and stratified meta-analyses.
| Model (Comparison) | Subgroup | No. of trials | I2(%) | Pa | Fixed | Random | P for bias |
|---|---|---|---|---|---|---|---|
| homozygote comparison (Asn/Asn vs. Asp/Asp) | Total | 95 | 68.3 | 0 | 1.103(1.052,1.157) | 1.170(1.060,1.293) | 0.079 |
| PB | 41 | 79.8 | 0 | 1.037(0.977,1.101) | 1.074(0.922,1.250) | 0.53 | |
| HB | 49 | 39 | 0.004 | 1.249(1.149,1.358) | 1.283(1.135,1.450) | 0.462 | |
| Asia | 30 | 48.3 | 0.003 | 1.664(1.461,1.894) | 1.734(1.371,2.192) | 0.961 | |
| Caucasian | 37 | 50.8 | 0 | 0.964(0.899,1.034) | 1.019(0.913,1.137) | 0.041 | |
| PCR | 29 | 65 | 0 | 1.041(0.951,1.140) | 1.175(0.983,1.404) | 0.054 | |
| PCR-RFLP | 38 | 62.5 | 0 | 1.160(1.068,1.260) | 1.238(1.053,1.455) | 0.054 | |
| Taqman | 18 | 24.8 | 0.163 | 1.003(0.921,1.093) | 0.983(0.878,1.100) | 0.16 | |
| Bladder cancer | 12 | 56.4 | 0.008 | 1.370(1.198,1.566) | 1.446(1.160,1.803) | 0.191 | |
| Breast cancer | 18 | 66.6 | 0 | 1.098(1.009,1.194) | 1.042(0.871,1.246) | 0.543 | |
| Esophageal cancer | 7 | 0 | 0.62 | 1.219(0.945,1.571) | 1.243(0.962,1.608) | 0.074 | |
| Gastric cancer | 8 | 65.3 | 0.005 | 1.517(1.167,1.972) | 1.876(1.105,3.186) | 0.258 | |
| Head and neck cancer | 6 | 52.4 | 0.062 | 0.993(0.814,1.212) | 0.989(0.707,1.384) | 0.909 | |
| Lung Cancer | 16 | 0 | 0.533 | 1.043(0.901,1.207) | 1.042(0.899,1.207) | 0.386 | |
| Prostate cancer | 7 | 93.5 | 0 | 1.570(1.314,1.874) | 2.038(0.848,4.894) | 0.419 | |
| Skin Cancer | 7 | 59.9 | 0.021 | 0.784(0.689,0.893) | 0.818(0.657,1.020) | 0.448 | |
| Non- Hodgkin lymphoma | 6 | 0 | 0.782 | 0.998(0.811,1.229) | 1.000(0.812,1.231) | 0.505 | |
| heterozygote comparison (Asp/Asn vs. Asp/Asp) | Total | 95 | 61.1 | 0 | 1.106(1.072,1.141) | 1.133(1.072,1.198) | 0.111 |
| PB | 41 | 64.7 | 0 | 1.061(1.020,1.104) | 1.064(0.988,1.146) | 0.889 | |
| HB | 49 | 53.9 | 0 | 1.205(1.143,1.270) | 1.229(1.128,1.339) | 0.329 | |
| Asia | 30 | 71.8 | 0 | 1.373(1.275,1.480) | 1.287(1.105,1.499) | 0.096 | |
| Caucasian | 37 | 0 | 0.801 | 1.034(0.988,1.083) | 1.034(0.987,1.082) | 0.526 | |
| PCR | 29 | 44.2 | 0.006 | 1.057(0.996,1.121) | 1.076(0.982,1.180) | 0.281 | |
| PCR-RFLP | 38 | 70 | 0 | 1.187(1.126,1.251) | 1.203(1.081,1.338) | 0.745 | |
| Taqman | 18 | 14.5 | 0.28 | 1.030(0.974,1.090) | 1.039(0.973,1.109) | 0.348 | |
| Bladder cancer | 12 | 31.2 | 0.142 | 1.235(1.128,1.353) | 1.265(1.125,1.423) | 0.231 | |
| Breast cancer | 18 | 70.7 | 0 | 1.086(1.025,1.149) | 1.101(0.972,1.248) | 0.42 | |
| Esophageal cancer | 7 | 0 | 0.994 | 1.213(1.051,1.401) | 1.213(1.051,1.401) | 0.932 | |
| Gastric cancer | 8 | 91.1 | 0 | 1.209(1.038,1.409) | 1.066(0.614,1.848) | 0.491 | |
| Head and neck cancer | 6 | 27.4 | 0.229 | 1.114(0.977,1.271) | 1.121(0.950,1.323) | 0.334 | |
| Lung Cancer | 16 | 0 | 0.808 | 1.000(0.918,1.090) | 1.001(0.918,1.091) | 0.294 | |
| Prostate cancer | 7 | 78.4 | 0 | 1.281(1.140,1.440) | 1.297(0.965,1.743) | 0.879 | |
| Skin Cancer | 7 | 36.5 | 0.15 | 1.018(0.938,1.105) | 1.023(0.913,1.146) | 0.868 | |
| Non- Hodgkin lymphoma | 6 | 27.7 | 0.227 | 1.038(0.907,1.187) | 1.047(0.881,1.244) | 0.938 | |
| dominant model((Asn/Asn+Asp/Asn) vs. Asp/Asp) | Total | 95 | 69.3 | 0 | 1.110(1.078,1.143) | 1.143(1.078,1.212) | 0.126 |
| PB | 41 | 75.9 | 0 | 1.060(1.021,1.101) | 1.067(0.981,1.160) | 0.754 | |
| HB | 49 | 56.6 | 0 | 1.217(1.158,1.278) | 1.237(1.139,1.343) | 0.587 | |
| Asia | 30 | 73.4 | 0 | 1.416(1.321,1.518) | 1.336(1.153,1.547) | 0.13 | |
| Caucasian | 37 | 3.2 | 0.414 | 1.020(0.976,1.065) | 1.021(0.976,1.068) | 0.102 | |
| PCR | 29 | 47.4 | 0.003 | 1.053(0.996,1.113) | 1.091(0.999,1.191) | 0.137 | |
| PCR-RFLP | 38 | 74.5 | 0 | 1.191(1.133,1.251) | 1.216(1.091,1.356) | 0.647 | |
| Taqman | 18 | 11.5 | 0.317 | 1.026(0.972,1.082) | 1.028(0.968,1.093) | 0.908 | |
| Bladder cancer | 12 | 50.2 | 0.024 | 1.266(1.162,1.379) | 1.309(1.148,1.494) | 0.242 | |
| Breast cancer | 17 | 73.4 | 0 | 1.091(1.034,1.151) | 1.083(0.958,1.223) | 0.962 | |
| Esophageal cancer | 7 | 0 | 0.989 | 1.214(1.057,1.394) | 1.214(1.057,1.394) | 0.236 | |
| Gastric cancer | 8 | 90.7 | 0 | 1.277(1.106,1.474) | 1.229(0.745,2.027) | 0.88 | |
| Head and neck cancer | 6 | 50.7 | 0.071 | 1.091(0.963,1.236) | 1.104(0.908,1.343) | 0.493 | |
| Lung Cancer | 15 | 0 | 0.763 | 1.010(0.931,1.097) | 1.010(0.931,1.097) | 0.474 | |
| Prostate cancer | 7 | 89.8 | 0 | 1.353(1.213,1.509) | 1.407(0.951,2.081) | 0.71 | |
| Skin Cancer | 7 | 37.6 | 0.142 | 0.968(0.895,1.046) | 0.978(0.877,1.090) | 0.682 | |
| Non- Hodgkin lymphoma | 6 | 9.4 | 0.356 | 1.033(0.909,1.173) | 1.035(0.901,1.189) | 0.932 | |
| recessive model (Asn/Asn vs. (Asp/Asp+Asp/Asn)) | Total | 95 | 62.7 | 0 | 1.059(1.013,1.108) | 1.108(1.016,1.208) | 0.098 |
| PB | 41 | 76.4 | 0 | 1.010(0.954,1.069) | 1.044(0.914,1.192) | 0.501 | |
| HB | 49 | 30.6 | 0.025 | 1.157(1.070,1.252) | 1.178(1.059,1.310) | 0.481 | |
| Asia | 30 | 35.8 | 0.032 | 1.445(1.275,1.637) | 1.515(1.240,1.852) | 0.668 | |
| Caucasian | 37 | 52.2 | 0 | 0.954(0.894,1.019) | 1.006(0.906,1.115) | 0.055 | |
| PCR | 29 | 64.2 | 0 | 1.022(0.939,1.113) | 1.131(0.959,1.335) | 0.107 | |
| PCR-RFLP | 38 | 53 | 0 | 1.087(1.006,1.175) | 1.147(1.002,1.314) | 0.152 | |
| Taqman | 18 | 28.8 | 0.123 | 0.987(0.911,1.609) | 0.958(0.859,1.069) | 0.082 | |
| Bladder cancer | 12 | 48.6 | 0.029 | 1.225(1.080,1.389) | 1.271(1.052,1.536) | 0.189 | |
| Breast cancer | 17 | 60.1 | 0.001 | 1.062(0.981,1.149) | 1.018(0.874,1.186) | 0.421 | |
| Esophageal cancer | 7 | 0 | 0.615 | 1.102(0.869,1.398) | 1.130(0.888,1.437) | 0.086 | |
| Gastric cancer | 8 | 39 | 0.119 | 1.563(1.215,2.011) | 1.739(1.190,2.541) | 0.341 | |
| Head and neck cancer | 6 | 35.4 | 0.171 | 0.951(0.790,1.144) | 0.944(0.729,1.223) | 0.815 | |
| Lung Cancer | 15 | 0 | 0.806 | 1.046(0.910,1.203) | 1.046(0.910,1.203) | 0.495 | |
| Prostate cancer | 7 | 92.4 | 0 | 1.406(1.186,1.667) | 1.851(0.846,4.050) | 0.357 | |
| Skin Cancer | 7 | 63.4 | 0.012 | 0.781(0.691,0.883) | 0.810(0.653,1.006) | 0.557 | |
| Non- Hodgkin lymphoma | 6 | 0 | 0.619 | 0.987(0.813,1.200) | 0.989(0.814,1.203) | 0.646 |
a P for heterogeneity.